HKW Portfolio Company Infab Acquires Another Complementary Product Line

HKW advises this add-on acquisition immediately expands the product offering and customer base.

HKW, a middle-market private equity firm focused on growth-oriented companies; today announced that its portfolio company, Infab, LLC (“Infab”), has acquired the glove division of International Biomedical, Ltd.

The gloves are designed to reduce the amount of radiation exposure during surgical procedures. The financial terms of the transaction were not disclosed.

“This acquisition is a very logical fit with Infab as it adds a radiation protection product of exceptional quality to our offering,” said Daren Dickerson, CEO of Infab. “The Infab team is very excited to add these gloves to our production so that we can be more responsive in providing critical products to healthcare professionals.”

“John Segars, CEO of International Biomedical, has done a remarkable job building the glove business. We are very pleased to bring this excellent product line to leading healthcare customers worldwide,“ said Kent Robinson, HKW Partner and Chairman of the Board for Infab. “HKW’s emphasis on partnering in the health and wellness industry remains a key area of focus; this add-on strengthens our commitment to support the professionals within this sector.


Infab designs and builds lightweight, comfortable, and technologically advanced radiation protection products. Infab’s PPE products enable health care providers and patients to benefit from the diagnostic capabilities of imaging technology, functioning as a “one-stop-shop” for distributors and customers.

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.